PharmaResearch Rejuran earnings show Q3 revenue up 27%, driven by exports. Operating profit rose only 1.2%, revealing a more mixed picture.
Exports lift sales
PharmaResearch Rejuran earnings drew attention on 6 November 2026 after the South Korean company reported strong third-quarter growth. Consolidated revenue reached KRW171.5 billion, approximately 27% higher than a year earlier. The company sells medical devices, cosmetics and pharmaceutical products, including the Rejuran injectable franchise. However, the profit figures tell a more nuanced story.
Revenue rose faster than profit
Operating profit reached KRW62.6 billion, up approximately 1.2% year on year. The operating margin was about 36.5%. Net profit fell 40.5% to KRW30.2 billion, according to Korean financial reporting. This means stronger sales did not translate into equivalent earnings growth. The figures are preliminary company disclosures, not a clinical assessment of any treatment.
International expansion is central
Medical-device exports were approximately KRW30 billion, up 53% from a year earlier. Cosmetics exports rose 92% to KRW42.1 billion. Reported markets contributing to device growth include France, Singapore, Indonesia and the Czech Republic. PharmaResearch also outlined plans to expand in the Middle East and Latin America, including the UAE, Mexico, Argentina and Chile. These are commercial intentions, not proof that regulatory authorization has been obtained in every market.
What this means for regenerative aesthetics
The results illustrate the commercial momentum behind polynucleotide and skin-quality products. Yet financial growth should not be mistaken for evidence of clinical superiority. Regulatory status, approved indications and evidence quality differ by product and jurisdiction. Moreover, terms such as regenerative and skin repair can be used broadly in marketing. Clinicians and patients should distinguish biological claims from outcomes demonstrated in controlled trials.
A market signal, not a clinical verdict
The company’s sales show international demand. Its modest operating-profit increase also suggests that expansion has costs. Future filings will clarify whether growth can remain profitable. For the aesthetic sector, the more useful question is how commercial adoption will be matched by independent clinical evidence.
Sources
https://en.sedaily.com/finance/2026/11/06/pharmaresearch-q3-revenue-jumps-27-percent-on-rejuran
https://heyholder.com/en/stock/KR7214450009/disclosures
Disclaimer
This article is published by Aesthetics.news for general information and educational purposes only. It does not constitute medical advice, diagnosis or treatment, and should not replace a consultation with a qualified healthcare professional. Treatments and outcomes may vary from person to person. Readers should seek advice from an appropriately qualified professional before making decisions about their health or treatment. In a medical emergency, seek immediate medical assistance.